Latane,
It sure is becoming increasingly obvious leronlimab is being purposely shunned. Approval should have happened over a hundred thousand lives ago, but small minds have prevailed.
I give NP credit for trying an "end run" (going outside of the US). Further, as a CEO he has an unusual background which makes him quite valuable to us, leronlimab, Cytodyn and humanity. He's a newcomer, an Iranian, a survivor, AND he's not in with the "in-crowd." This is extremely important - his efforts go to bringing leronlimab as a powerful medication to mankind. He's not busy trying to fit in with the power elite, instead he's on a crusade - a GOOD crusade.
So Options
*Approval in the US (only when they have no other choice)
*Approval overseas - Some countries are desperate enough and since the US (through the misguided efforts of our president) has lost significant "sway" and prestige, might make decisions disregarding pressure from the US to shun Cytodyn/leronlimab.
*Move the company to a foreign country (thinking outside the box - a radical move and one that would have to be carefully and quietly planned). If the goal is to make leronlimab available...
*Capitulate and be absorbed by BP. (Bad idea - leronlimab is too disruptive to their product lines - so it would be bought up to be put "on the shelf")
Suggestion - expedite LONG-HAULER/leronlimab study
Organized groups of long haulers (frustrated, angry, potential Bull-moose screamers and their supporters) already exist. It's a matter of getting them involved, focused, and utilize their communication networks to spread the word, influence, pressure, etc.
Also it changes the game. We're no longer competing for the cure/vaccine/treatment of Covid19 (wink). Instead we're competing with a smaller group that is seeking treatments for the immunological effects resulting from Covid19.
And...If the EINDs are any indication (along with the results after three days with the M-M study), we can be reasonably confident about the outcome. Should be easy to populate the study (folks will be clamoring to get in) and it won't be a long, drawn-out affair. Should know after day three, seven and fourteen if it is as effective as we suspect.
Slam dunk
Market Data 
Markets 
AI
